Histogenics Corporation 2015 Form 10-K Summary
Filing identity: The submitted filing is for Histogenics Corporation, not Ocugen, Inc. It reports the fiscal year ended December 31, 2015; the filing is an annual Form 10-K rather than a quarterly report.
Business context and reporting period
Histogenics was a clinical-stage regenerative medicine company developing musculoskeletal products, primarily NeoCart, an autologous cell- and scaffold-based implant for knee cartilage defects. NeoCart was being evaluated in a 245-patient Phase 3 trial under an FDA Special Protocol Assessment. The company had no FDA-approved products and generated no product or collaboration revenue in 2015 or 2014.
- Phase 3 enrollment reached 114 patients by December 31, 2015, with 32 eligible sites.
- Management expected to complete enrollment by the end of the first half of 2017.
- Assuming successful trial results, management expected to submit a Biologics License Application in the second half of 2018 and potentially launch in 2019.
- The company employed 49 full-time employees at year-end.
Financial performance and liquidity
| Metric | 2015 | 2014 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No change |
| Research and development expense | $23.2 million | $26.0 million | Down $2.8 million |
| General and administrative expense | $8.3 million | $6.6 million | Up $1.7 million |
| Impairment of intangible assets | $0.3 million | $0.1 million | Increase |
| Loss from operations | $31.8 million | $32.7 million | Improved $0.8 million |
| Net loss | $32.0 million | $22.8 million | Worsened $9.2 million |
| Basic and diluted loss per share | $2.42 | $6.85 | Improved per share, partly reflecting a larger share base |
| Cash used in operating activities | $30.0 million | $17.9 million | Use increased $12.1 million |
| Cash used in investing activities | $1.9 million | $3.3 million | Use decreased $1.4 million |
| Cash provided by financing activities | $4.4 million | $71.1 million | Down $66.7 million |
| Cash and cash equivalents at year-end | $30.9 million | $58.5 million | Down $27.6 million |
Gross margin and operating margin are not meaningful because the company had no revenue. The accumulated deficit was $165.5 million at December 31, 2015. Total assets were $36.8 million, total liabilities were $8.6 million and stockholders’ equity was $28.2 million.
Debt consisted primarily of an equipment loan from Silicon Valley Bank. Borrowings outstanding were approximately $1.3 million at December 31, 2015, compared with $1.8 million at December 31, 2014. The company was in compliance with the loan covenants.
Material changes versus the prior comparable period
- Net loss increased substantially because 2014 included $9.9 million of other income, primarily from fair-value changes and settlements associated with liabilities that were extinguished or settled in connection with the IPO. 2015 had $0.2 million of net other expense.
- Research and development expense declined despite higher clinical and personnel activity because 2014 included a $10.0 million nonrecurring Intrexon technology-access charge.
- General and administrative expense increased due primarily to higher directors’ and officers’ insurance, personnel, stock-based compensation and recruiting costs.
- Operating cash burn increased to $30.0 million, while year-end cash declined by $27.6 million.
- The company raised $4.7 million from the partial exercise of the IPO underwriters’ overallotment option in 2015 and paid $0.4 million on its equipment loan.
- In November and December 2015, the company amended its Phase 3 protocol to expand eligibility, including patients with trochlear lesions and patients up to age 59; the FDA accepted the amendment in December.
- The company completed initial engineering runs and validation studies at its Lexington, Massachusetts facility and completed the final performance qualification campaign for collagen. Remaining raw-material manufacturing transitions were targeted for 2017.
Guidance, outlook, risks and unusual items
Management stated that existing cash and cash equivalents were expected to fund projected operations through the first quarter of 2017, but additional capital would be required to complete clinical development, manufacturing scale-up and potential commercialization. The estimate was expressly subject to change and could be shortened by higher-than-expected spending.
- Clinical risk: Enrollment had been slower than expected, and the company moved its anticipated enrollment completion from June 2016 to the first half of 2017. Phase 3 results may not replicate earlier Phase 1 and Phase 2 results.
- Manufacturing and regulatory risk: The company needed FDA acceptance of the comparability of raw materials produced in-house or by new suppliers. Delays or additional required studies could disrupt the Phase 3 trial or BLA timeline.
- Financing risk: Continued losses and negative operating cash flow made future equity, debt or partnership financing necessary. Financing could be unavailable, costly or dilutive.
- Commercial risk: NeoCart had not been approved, and future reimbursement, pricing, physician adoption, manufacturing capacity and market acceptance were uncertain.
- Collaboration obligations: The Intrexon agreement required the company to fund development costs, pay potential development and sales milestones, and share certain economics from collaboration products. Intrexon-related accrued expenses were $1.5 million at year-end.
- Intangible impairment: The company recorded a $0.3 million impairment charge in 2015 and indicated that further impairment could occur because development of the underlying acquired research asset had been delayed.
- Commitments: Minimum lease payments totaled $8.0 million as of December 31, 2015. A further $0.2 million was due under an engineering agreement for a multi-unit bioreactor, and $0.03 million remained payable under the collagen supply agreement.
- Controls: Management concluded that disclosure controls and internal control over financial reporting were effective as of December 31, 2015. The independent auditor audited the financial statements but was not engaged to audit internal control effectiveness.
Most important facts for investors to verify
- Confirm the issuer identity: the supplied document is Histogenics Corporation, while the request identifies Ocugen, Inc.
- Verify the full audited financial statements and notes, particularly cash runway, operating cash burn, debt maturities and financing requirements.
- Track Phase 3 enrollment, completion timing, retention, endpoint results and any FDA communications under the Special Protocol Assessment.
- Verify FDA acceptance of raw-material comparability, manufacturing-site readiness and the timing of any IND amendment or BLA submission.
- Review the Intrexon agreement for accrued costs, milestone obligations, royalties, termination rights and potential equity dilution.
- Assess whether the company obtained additional financing after year-end and whether funding was sufficient to continue operations beyond the projected first quarter of 2017.
- Review the impairment analysis for acquired in-process research and development and the potential for additional write-downs.